Answers are grounded in this paper and cite their sources.
The ARHGAP18 protein encoded by the SENEX gene has been implicated in tumor progression, yet its functional role in Burkitt lymphoma remains incompletely understood. We previously identified aberrant SENEX overexpression in relapsed and refractory Burkitt’s lymphoma, suggesting a potential link to therapy resistance. Here, we investigated SENEX as a regulator of stress-induced premature senescence (SIPS) and tumor cell fate. Chemotherapeutic stress increased SENEX expression together with senescence-associated markers, while SENEX overexpression reproduced selected senescence-associated features and reduced susceptibility to apoptosis. Mechanistically, SENEX modulation was associated with epithelial–mesenchymal transition (EMT)-related changes and WNT/β-catenin pathway activity, and SENEX overexpression increased lymphoma-cell invasive capacity. In vivo, SENEX-overexpressing xenografts showed a dissociation between primary subcutaneous tumor growth and overall survival, with relatively slower primary tumor growth but shortened survival. These findings indicate that chemotherapy-induced SIPS and SENEX overexpression produce overlapping but non-identical phenotypes and support SENEX/ARHGAP18 as a potential contributor to senescence-associated adaptation, apoptosis resistance, and invasive behavior in Burkitt lymphoma. Further studies are required to define the direct molecular link between ARHGAP18 and WNT/β-catenin signaling and to determine the mechanisms underlying the adverse survival phenotype.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: